Jazz Pharmaceuticals plc’s filing revealed that its Chairman & CEO COZADD BRUCE C unloaded Company’s shares for reported $0.19 million on Apr 01 ’25. In the deal valued at $123.75 per share,1,500 shares were sold. As a result of this transaction, COZADD BRUCE C now holds 440,307 shares worth roughly $44.8 million.
Then, COZADD BRUCE C bought 2,000 shares, generating $250,625 in total proceeds.
Before that, Iannone Robert sold 2,403 shares. Jazz Pharmaceuticals plc shares valued at $332,605 were divested by the EVP, Global Head of R&D & CMO at a price of $138.41 per share. As a result of the transaction, Iannone Robert now holds 79,621 shares, worth roughly $8.1 million.
UBS upgraded its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy from a a Neutral in a research note published on March 07, 2025; the price target was increased to $179 from $145. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late February from “an Overweight” to “a Neutral”. Wells Fargo also remained covering JAZZ and has increased its forecast on February 13, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Morgan Stanley revised its rating on December 12, 2024. It rated JAZZ as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of JAZZ
On Monday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock jump 1.24% to $101.75. Over the last five days, the stock has lost -4.84%. Jazz Pharmaceuticals plc shares have fallen nearly -17.38% since the year began. Nevertheless, the stocks have fallen -10.34% over the past one year. While a 52-week high of $148.06 was reached on 02/26/25, a 52-week low of $95.49 was recorded on 04/09/25. SMA at 50 days reached $129.64, while 200 days put it at $118.52.
Levels Of Support And Resistance For JAZZ Stock
The 24-hour chart illustrates a support level at 100.13, which if violated will result in even more drops to 98.52. On the upside, there is a resistance level at 103.40. A further resistance level may holdings at 105.06. The Relative Strength Index (RSI) on the 14-day chart is 29.03, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -13.62, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.12%. Stochastics %K at 13.49% indicates the stock is a buying.
How much short interest is there in Jazz Pharmaceuticals plc?
A steep rise in short interest was recorded in Jazz Pharmaceuticals plc stocks on 2025-03-31, dropping by 80974.0 shares to a total of 4.28 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 4.36 million shares. There was a decline of -1.89%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 05, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $169 price target.
